SCHEDULE: TCG Crossover Funds & Chen Yu Boost Vor Biopharma Stake

TCG Crossover Funds and Chen Yu disclose significant beneficial ownership in Vor Biopharma Inc., reaching 10.5% for Chen Yu following a recent offering.

Summary

• TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., TCG Crossover GP III, LLC, and TCG Crossover Fund III, L.P. each reported beneficial ownership of 2,836,539 shares of Vor Biopharma Inc. Common Stock, representing 5.2% of the class.
• Chen Yu, as the sole managing member of TCG Crossover GP II and TCG Crossover GP III, is deemed to beneficially own an aggregate of 5,673,078 shares, representing 10.5% of Vor Biopharma Inc.'s Common Stock.
• The beneficial ownership percentages are calculated based on a total of 54,185,582 shares of Common Stock outstanding, which includes 48,847,504 shares as of March 23, 2026, and an additional 5,338,078 shares issued in an underwritten offering that closed on March 30, 2026.
• The reporting persons expressly disclaim status as a group for purposes of this Schedule 13G.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of beneficial ownership, providing factual information without inherently positive or negative operational implications for the company, though the underlying capital raise has both positive (funding) and negative (dilution) aspects.

Positives

• Increased institutional ownership by TCG Crossover Funds and Chen Yu may signal confidence in Vor Biopharma Inc.'s future prospects.
• The recent underwritten offering successfully issued 5,338,078 shares, indicating the company's ability to raise capital.

Negatives

• The issuance of 5,338,078 new shares in the underwritten offering results in dilution for existing shareholders.

Risks

• The filing does not explicitly detail specific risks, but the nature of a biopharma company inherently involves risks related to clinical trials, regulatory approvals, and market acceptance of products.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

StockSavvy.ai notes that the disclosure of significant beneficial ownership by institutional investors like TCG Crossover Funds is a common occurrence in the biopharma sector, often following capital raises. Such filings provide transparency on major shareholder positions, which can be a factor in market sentiment for growth-oriented companies like Vor Biopharma.

Stakeholder Impact

• Shareholders: The recent offering led to dilution due to the issuance of 5,338,078 new shares. However, the increased institutional ownership by TCG Crossover Funds and Chen Yu could be viewed positively.
• Company: The capital raise from the underwritten offering provides additional funding for operations and strategic initiatives.

Key Dates

Keywords

Vor Biopharma, TCG Crossover, Chen Yu, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biopharma, Equity Offering, Shareholder